Clinical trial
BMS-214662 in Treating Patients With Solid Tumors
NCT00005973 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005973 |
|---|---|
| Title | BMS-214662 in Treating Patients With Solid Tumors |
| Official title | Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086D) in Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor |
| Intervention type | Drug, Other |
| Interventions | BMS-214662, laboratory biomarker analysis |
| Enrollment | 36 |
| Start date | Apr 1, 2000 |
| Primary completion | Jul 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: